What drove the recent MEM.AX stock volume spike?

The volume jump to **18,263,359** shares followed the earnings announcement and investor focus on Felix commercial progress. Short-term traders are reacting to revenue updates and liquidity signals while awaiting management commentary.

Does MEM.AX stock pay a dividend?

No. Memphasys currently has no dividend yield reported. The company is reinvesting in product development and working capital, and the payout ratio is **0.00**.

What are the main valuation risks for MEM.AX stock?

Valuation risks include an elevated price-to-sales of **37.82**, low current ratio **0.25**, long receivable days (**624**), and negative margins. These metrics heighten the risk of dilution or capital raising.

What catalysts could lift MEM.AX stock in coming months?

Key catalysts are new IVF clinic contracts for Felix, recurring consumables sales, regulatory clearances, and any favourable distribution deals. Positive updates on these items would materially affect the MEM.AX stock outlook.

AU Stocks

Earnings Due: Memphasys (MEM.AX) ASX pre-market 27 Feb 2026: catalyst for re-rate

ByDanny Kontos February 27, 2026February 27, 2026

MEM.AX stock heads into an earnings update pre-market on 27 Feb 2026 after a recent volume surge to 18,263,359 shares. Investors will watch revenue growth, cash position and product traction for Felix and related diagnostics. The company reported FY revenue growth of 7.78% but persistent net losses and low liquidity. This earnings spotlight links results to near-term price drivers and trading signals for small-cap biotech on the ASX.